- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Good News for Sanofi-Aventis: Heart Drug Multaq Receives FDA Approval
-
FDA Helps Investors Look Past Box Warnings
-
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
-
Smaller Pharma Wins the 'Most Valuable' Race
-
Sanofi-Aventis's 'Voluntary' Staff Departures
-
Sanofi-Aventis Stock Recovering After Lantus Leak
-
20 'Bathwater Babies' and 4 'Dogs with Fleas' for the Week
-
Monday's Options Recap
-
How Bad Is Sanofi's Safety Scare?
-
Friday's Options Recap
-
Friday Options Update: TLT, SNY, NKE, TIBX, VALE, ROST
-
Expect FDA Approval of AMAG Pharmaceutical's Feraheme
-
Thursday's Options Recap
-
Invest in Crucell's Rabies Vaccine
-
ADR Overview - Which Stocks Look Good, Which Don't
-
ADA Meeting 2009: Novel Diabetes Therapies Presented
-
Pharma Announces $80B Reduction: Who Wins?
-
Redefining Pharma as Biotech Dominates Industry's Growth
-
Global Pharma Outlook Negative as Patents Expire
-
Amgen's Better than Expected Portfolio Outlook
-
Companies Involved in the Treatment of Swine Flu
-
FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, SOMX, VPHM
-
Keryx: Another Beneficiary of the ASCO Effect
-
Why We're Cautious on The Medicines Company
-
Drug Stocks That Are Under the Radar
-
Two Potential Mega Biotech Deals Fuel Industry Hopes
-
Big Pharma's Pheeding Phrenzy
-
Berkshire Hathaway Stock Holdings and Investment Ideas
-
Fortune 40 Best Stocks for Retirement: Part IV
-
AstroZeneca: Brilinta News Not a Panacea
-
Access Pharma: Low Valuation, Big Potential
-
40 Best Stocks to Retire On - Fortune
-
FDA Calendar Updates: AstraZeneca, GlaxoSmithKline, Sanofi-Aventis
-
Pharmaceutical Stocks Remain a Buy
-
Preview from Europe: Swine Flu, Stress Tests and Green Shoots
-
Supreme Court Denies Aventis' Cert Petition in Lovenox Case
-
Bright Prospects for Micromet (Part 2)
-
Sanofi-Aventis Reaffirms Commitment to China Public Health with New Facility
-
Why Abbott Labs Is Getting Closer to a Buy
-
Bristol-Myers Squibb: An Attractive Value
-
Wall Street Breakfast: Must-Know News